Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 286

Results For "Pan"

9228 News Found

AstraZeneca to launch DTC medication platform, offering up to 70% discounts on Farxiga, Airsupra
Supply Chain | September 30, 2025

AstraZeneca to launch DTC medication platform, offering up to 70% discounts on Farxiga, Airsupra

The platform is being introduced to expand access to treatments for people living with chronic conditions


GSK names Luke Miels as next CEO
People | September 30, 2025

GSK names Luke Miels as next CEO

Miels will formally assume the role on January 1, 2026


FDA authorizes first eyeglass lenses to slow progression of pediatric Myopia
News | September 30, 2025

FDA authorizes first eyeglass lenses to slow progression of pediatric Myopia

FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses


Sanofi boosts Sanofi Ventures with additional $625 million September 24, 2025
Digitisation | September 29, 2025

Sanofi boosts Sanofi Ventures with additional $625 million September 24, 2025

Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies


Aptar Pharma opens new R&D center in France
News | September 29, 2025

Aptar Pharma opens new R&D center in France

Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world


Lilly opens biotech in San Diego
Startup | September 29, 2025

Lilly opens biotech in San Diego

82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines


FDA approves Eli Lilly’s Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Drug Approval | September 29, 2025

FDA approves Eli Lilly’s Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor


AstraZeneca to harmonise its listing structure across LSE, STO and NYSE
News | September 29, 2025

AstraZeneca to harmonise its listing structure across LSE, STO and NYSE

Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs